{'fraction_non_alphanumeric': 0.02857142857142857, 'fraction_numerical': 0.007881773399014778, 'mean_word_length': 5.157575757575757, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Association between cancer risk and HLA genotype can be explained by anti-tumor immunity


 Over recent decades, efforts to explain the heritability of developing cancer have focused on identifying high-risk genes and common genetic variants. However, no studies considered genetic factors regulating tumor-specific immune responses. By developing a novel human leukocyte antigen (HLA) score, determined by autologous HLA allele-binding epitopes of tumor-specific antigens, we showed that individuals with HLA allele sets supporting broader tumor-specific T cell responses have lower risk of developing melanoma. The risk ratio between the highest risk and most protected groups was 5.69 comparing the top and bottom 20% of the HLA score distribution (p < 0.05). Similar results were obtained for other cancers, including non-small cell lung, renal, and bladder cancers, but not colorectal cancer. Our findings suggest that subjects with a low HLA score have an increased genetic risk of developing certain cancers.